March 28, 2021 – Recent reports from the United Kingdom (UK) and from throughout the European Union (EU) have suggested that the SARS-CoV-2 (Covid-19) vaccine made by AstraZeneca was at the origin of the development of a very rare type …

Covid-19 Vaccines: Is there genetic predisposition for thrombosis? Read more »

August 26, 2016 – Eltrombopag is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts). It is a small molecule agonist of the c-mpl (TpoR) receptor, which is the physiological target of the hormone thrombopoietin. Eltrombopag is approved and on the market under the trade name Promacta in the US …

Eltrombopag (Revolade) can cause severe hepatotoxicity and potentially fatal liver injury Read more »

May 13, 2010 – The American Food and Drug Administration (FDA) posted yesterday the following Safety Information Text (italic): GlaxoSmithKline and FDA notified healthcare professionals of a new safety finding in patients with thrombocytopenia due to chronic liver disease treated …

Eltrombopag [Promacta]: Portal Venous System Thromboses in Study of Patients With Chronic Liver Disease Read more »